Gamabufotalin inhibits colitis-associated colorectal cancer by suppressing transcription factor STAT3.
Eur J Pharmacol
; 966: 176372, 2024 Mar 05.
Article
en En
| MEDLINE
| ID: mdl-38301817
ABSTRACT
Constitutive activation of STAT3 plays important role in the pathogenesis of colorectal cancer (CRC). Inhibition of STAT3 has been proposed as a reasonable strategy to suppress CRC. Gamabufotalin (Gam), an effective bioactive compound of ChanChu, has been used for cancer therapy due to its desirable metabolic stability and less adverse effect. However, its effect on CRC is still unclear. In this study, we found that Gam significantly inhibited the CRC in vitro and vivo. Furthermore, Gam induced apoptosis to inhibit the viability of HCT-116 and HT-29 cell lines in dose-dependent manner by suppressing the transcription factor STAT3. In addition, Gam was also found to inhibit carcinogenesis of colitis-associated cancer (CAC) in AOM/DSS mice model by inhibiting STAT3. Our findings suggest that Gam may be an effective way to prevent occurrence and development of CRC and CAC.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Bufanólidos
/
Neoplasias Colorrectales
/
Colitis
/
Neoplasias Asociadas a Colitis
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Eur J Pharmacol
Año:
2024
Tipo del documento:
Article